A project called APO-DECIDE (Apoptosis Modelling for Treatment Decisions in
Colorectal Cancer) has received EU FP7 funding. This initiative is led by RCSI, Professor Jochen Prehn, in conjunction with OncoMark Ltd., Queen’s University Belfast, Université Paris Descarte, Optimata Ltd. and Klinikum Der Johann Wolfgang Von Goethe Universitaet, ‘APO-DECIDE’ will create tools and tests to help oncologists
predict which patients will benefit from certain forms of therapy. The
two-year project began in November 2012.
For more information please see Apo-Decide project website